Glaukos Co. (NYSE:GKOS) Shares Acquired by Victory Capital Management Inc.

Victory Capital Management Inc. increased its holdings in Glaukos Co. (NYSE:GKOS - Free Report) by 421.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 79,211 shares of the medical instruments supplier's stock after purchasing an additional 64,031 shares during the period. Victory Capital Management Inc. owned 0.14% of Glaukos worth $10,320,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in Glaukos by 1.4% during the first quarter. Vanguard Group Inc. now owns 5,308,897 shares of the medical instruments supplier's stock worth $500,576,000 after purchasing an additional 72,159 shares during the period. Fred Alger Management LLC raised its position in shares of Glaukos by 3.8% in the 2nd quarter. Fred Alger Management LLC now owns 1,278,723 shares of the medical instruments supplier's stock worth $151,337,000 after buying an additional 47,308 shares during the period. Primecap Management Co. CA boosted its holdings in Glaukos by 43.9% in the second quarter. Primecap Management Co. CA now owns 1,220,815 shares of the medical instruments supplier's stock valued at $144,483,000 after acquiring an additional 372,180 shares during the last quarter. Driehaus Capital Management LLC boosted its holdings in Glaukos by 24.0% in the second quarter. Driehaus Capital Management LLC now owns 803,650 shares of the medical instruments supplier's stock valued at $95,112,000 after acquiring an additional 155,653 shares during the last quarter. Finally, Point72 Asset Management L.P. purchased a new stake in Glaukos during the second quarter valued at about $67,460,000. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Glaukos Stock Performance

Shares of GKOS opened at $141.44 on Thursday. Glaukos Co. has a one year low of $59.22 and a one year high of $145.84. The stock has a 50-day moving average price of $131.75 and a 200 day moving average price of $123.18. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71.

Glaukos (NYSE:GKOS - Get Free Report) last released its earnings results on Monday, November 4th. The medical instruments supplier reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.20. The company had revenue of $96.70 million during the quarter, compared to analysts' expectations of $91.50 million. Glaukos had a negative return on equity of 18.99% and a negative net margin of 42.43%. The business's revenue was up 23.9% on a year-over-year basis. During the same period in the prior year, the business posted ($0.50) EPS. On average, equities analysts forecast that Glaukos Co. will post -1.96 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Gilbert H. Kliman sold 3,000 shares of the firm's stock in a transaction on Monday, September 9th. The stock was sold at an average price of $130.67, for a total transaction of $392,010.00. Following the transaction, the director now directly owns 32,336 shares in the company, valued at $4,225,345.12. This trade represents a 8.49 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Joseph E. Gilliam sold 2,275 shares of the stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $138.97, for a total transaction of $316,156.75. Following the sale, the chief operating officer now directly owns 102,169 shares in the company, valued at $14,198,425.93. This trade represents a 2.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 6.40% of the stock is owned by company insiders.

Analysts Set New Price Targets

GKOS has been the topic of several research analyst reports. Needham & Company LLC lifted their price objective on Glaukos from $131.00 to $137.00 and gave the company a "buy" rating in a research note on Thursday, August 1st. Piper Sandler set a $140.00 price target on shares of Glaukos in a research report on Thursday, October 17th. BTIG Research increased their price objective on shares of Glaukos from $131.00 to $139.00 and gave the stock a "buy" rating in a research report on Wednesday, August 28th. Truist Financial raised their target price on shares of Glaukos from $145.00 to $152.00 and gave the company a "buy" rating in a research note on Monday, October 14th. Finally, JPMorgan Chase & Co. upped their price target on shares of Glaukos from $130.00 to $145.00 and gave the stock an "overweight" rating in a research report on Tuesday, November 5th. Four equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $134.55.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.